Tracked deals
5
5 tracked deals across 2021-2025.
New York, New York, United States
Signet Healthcare Partners is a healthcare growth equity firm that provides growth capital to commercial-stage healthcare companies, primarily in pharmaceuticals and medical technology.
Tracked deals
5
5 tracked deals across 2021-2025.
Recent pace
1
1 tracked deal announced in the last 12 months.
Deal mix
Growth capital
2 growth capital · 1 addon · 1 divestiture
Last 3 years
Supporting Data
PainTEQ, a Tampa-based developer of minimally invasive sacroiliac (SI) joint implants, completed a majority growth recapitalization co-led by Signet Healthcare Partners and Windham Capital Partners with a new equity investment from MVolution Partners. The capital will fund clinical studies, next-generation product development and expansion of PainTEQ's U.S. commercial presence; transaction terms were not disclosed.
Laborie Medical Technologies has completed the acquisition of GI Supply, a specialist maker of endoscopy and paracentesis products. GI Supply and its employees will be fully integrated into Laborie to expand the company's gastroenterology product portfolio and commercial capabilities; the deal is supported by Laborie's majority owner Patricia Industries and growth-equity partner Signet Healthcare Partners.
Signet Healthcare Partners, a New York-based healthcare growth equity firm, has completed a growth equity investment in Canadian specialty generics company Juno Pharmaceuticals Corp. Juno will use the proceeds to expand its complex and high-value generic and biosimilar portfolio and accelerate its growth and pipeline development in Canada and international markets.
An investor consortium led by Signet Healthcare Partners with Bionpharma, Inc. and GMS Capital Partners formed Pharma Nobis, LLC to acquire Fagron's U.S. contract manufacturing business and manufacturing facility in Texarkana, Texas. Fagron will retain a 20% interest in the new company; Todd Daviau was named CEO and the investors said they will seek to grow the contract manufacturing and private-label capabilities for consumer healthcare and retail customers.
Signet Healthcare Partners, a New York-based growth equity firm, has made a growth equity investment in Ascendia Pharmaceuticals, a North Brunswick, New Jersey-based specialty CDMO. The proceeds will fund Ascendia's facility expansion and increased manufacturing capacity; Signet principals James Gale and Dr. Theron Odlaug will join Ascendia's board.
Turn tracked acquisition activity into an outreach-ready buyer list.